Shire announced the launch of Cuvitru (immune globulin subcutaneous [human], 20% solution) indicated as replacement therapy for primary humoral immunodeficiency (PI) in patients aged ≥2 years. 

Cuvitru was initially approved by the Food and Drug Administration (FDA) in September 2016. It is the first subcutaneous 20% treatment option without proline launched in the United States to treat this patient population. It is also the only 20% subcutaneous immune globulin that allows for infusions up to 60mL (12g) per site and up to 60mL/hr per site, as tolerated. Compared to other standard subcutaneous immune globulin treatments, Cuvitru requires fewer infusion sites and shorter infusion times.  

Related Articles

Cuvitru provides a broad spectrum of opsonizing and neutralizing immune globulin G (IgG) antibodies against a wide variety of bacterial and viral agents. It also contains a spectrum of antibodies that can interact with and alter the activity of immune system cells and antibodies that can react with cells such as erythrocytes. 

Cuvitru is available as single-use vials containing 1g (5mL), 2g (10mL), 4g (20mL), and 8g (40mL) protein. 

For more information call (800) 999-1785 or visit